Biologicals and biosimilars: safety issues in Europe-Reference-Cited by-同舟云学术

Biologicals and biosimilars: safety issues in Europe

Published:2017-05-25 Issue:7 Volume:17 Page:871-877
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Portela Maria da Conceição Constantino¹^ORCID,Sinogas Carlos²³^ORCID,Albuquerque de Almeida Fernando⁴,Baptista-Leite Ricardo¹⁵^ORCID,Castro-Caldas Alexandre¹^ORCID

Affiliation:

1. Instituto de Ciências da Saúde, Universidade Católica Portuguesa, Lisboa, Portugal

2. ACF – Acompanhamento Farmacoterapêutico, Lda, Pavia, Portugal

3. Departamento de Biologia, Escola de Ciências e Tecnologia, Universidade de Évora, Évora, Portugal

4. Institute of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands

5. Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands

Funder

Universidade Católica Portuguesa

Roche Farmacêutica Química Lda.

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2017.1330409

Reference43 articles.

1. Overhauling oversight—European drug legislation

2. Improved guidelines will optimize efficacy and minimize adverse effects of biosimilar drugs

3. Assessing the Safety and Comparative Effectiveness of Follow-On Biologics (Biosimilars) in the United States

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Use of Off-Label MVASI in the Treatment of Patients With Neovascular AMD and DME;Translational Vision Science & Technology;2024-07-23

2. SAFETY OF BIODRUGS- PHARMACISTS’ KNOWLEDGE AND PRACTICE WITH REGARD TO POLISH AND EUROPEAN LEGAL ASPECTS AND SUBSTITUTION OF BIOTECHNOLOGY DRUGS: MULTICENTER STUDY IN POLAND.;Acta Poloniae Pharmaceutica - Drug Research;2020-10-09

3. Postmarketing Safety of Biosimilars: Current Status, Challenges, and Opportunities in the Spontaneous Reporting System;Therapeutic Innovation & Regulatory Science;2020-01-06

4. Efficacy and Safety in the Continued Treatment With a Biosimilar Drug in Patients Receiving Infliximab: A Systematic Review in the Context of Decision-Making From a Latin-American Country;Frontiers in Pharmacology;2019-11-15

5. Postmarketing Safety of Biosimilars: Current Status, Challenges, and Opportunities in the Spontaneous Reporting System;Therapeutic Innovation & Regulatory Science;2019-09-26